---

---

cancer   published : Yesterday   

save search

---

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology Annual Meeting
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
FGEN | $0.9844 -8.0% -8.7% 2.2M |

Health Technology

| Email alert Add to watchlist
fg-3246 cancer meeting study

---

Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Published: 2024-04-24 (Crawled : 19:00) - biospace.com/
NVCR | $12.35 2.45% 2.39% 1.1M |

Health Technology

| 2.41% | O: 0.33% H: 2.48% C: 2.07%
lung asco cancer cell for trial results

---

First Approval for Rare Pediatric Cancer; New OTC Opioid Overdose Option
Published: 2024-04-24 (Crawled : 16:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -0.27% | O: 0.8% H: 0.0% C: -1.05%
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| 2.43% | O: -0.03% H: 2.66% C: 2.46%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -1.02% | O: -1.02% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| -0.65% | O: -0.82% H: 0.37% C: 0.17%
XOMA | $25.11 -3.76% -3.9% 8.2K |

Health Technology

| -1.72% | O: 0.19% H: 0.0% C: -1.91%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.82% | O: 0.82% H: 0.0% C: 0.0%
rare first opioid approval for

---

Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO
Published: 2024-04-24 (Crawled : 14:00) - globenewswire.com
SNYNF | News | $94.25 -2.18% 480 |

Health Technology

| -0.27% | O: 0.8% H: 0.0% C: -1.05%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 0.82% | O: 0.82% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K |

Health Technology

| -0.09% | O: -0.05% H: 0.97% C: -0.04%
asco tumors treatment blood for

---

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
KTTA | $7.09 -1.19% 910 |

| -1.97% | O: -2.68% H: 0.72% C: 0.72%
pas-004 first trial therapeutics

---

Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
Published: 2024-04-24 (Crawled : 12:00) - globenewswire.com
BNGO | $0.7655 -3.64% -3.78% 790K |

Health Technology

| -4.39% | O: -0.62% H: 2.53% C: -3.8%
cancer publication

---

HOOKIPA Pharma Announces FDA Clearance of its Investigational New Drug Application for HB-700 for the Treatment of KRAS-Mutated Cancers
Published: 2024-04-24 (Crawled : 11:00) - globenewswire.com
HOOK | $0.843 10.2% 9.25% 10M |

Health Technology

| 15.02% | O: 10.96% H: 6.1% C: 3.66%
hb-700 fda pharma drug treatment clearance for application

---

Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
Published: 2024-04-23 (Crawled : 00:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K |

Manufacturing

| -0.21% | O: -1.05% H: 0.85% C: 0.85%
TAK | News | $13.23 -1.12% 0.0% 920K |

Health Technology

| -0.86% | O: -0.19% H: 0.08% C: -0.68%
granted approval cancer treatment for

---

FDA Rejects Abeona’s Gene Therapy, Approves ImmunityBio’s Bladder Cancer Treatment
Published: 2024-04-23 (Crawled : 13:30) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K |

Health Technology

| 3.89% | O: 0.13% H: 1.89% C: 1.3%
JNJ | News | $148.53 -0.69% -0.14% 9.6M |

Health Technology

| -0.13% | O: 0.89% H: 0.0% C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M |

Health Technology

| -0.17% | O: 0.56% H: 0.41% C: -0.07%
SNY | News | $46.66 -2.16% -2.21% 1.7M |

Health Technology

| 2.53% | O: 1.7% H: 0.0% C: 0.0%
fda bladder cancer treatment

---

Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy
Published: 2024-04-23 (Crawled : 12:30) - globenewswire.com
ARTL | News | $1.31 0.0% 5.4K |

Health Technology

| 3.08% | O: 0.77% H: 2.29% C: 0.0%
cancer publication therapy

---

PDS Biotech to Host Key Opinion Leader Event to Discuss Positive, Updated Data from Phase 2 VERSATILE-002 Clinical Trial with Versamune® HPV in Combination with KEYTRUDA® in Recurrent or Metastatic Head and Neck Cancer
Published: 2024-04-23 (Crawled : 12:00) - globenewswire.com
PDSB | $3.26 1.88% 1.84% 450K |

Health Technology

| 21.72% | O: 12.36% H: 8.33% C: 6.67%
atile-002 versamune biotech hpv cancer key trial

---

BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer
Published: 2024-04-23 (Crawled : 12:00) - biospace.com/
BGNE | $144.0 3.61% 3.48% 220K |

Health Technology

| 9.88% | O: 3.5% H: 4.77% C: 2.39%
lung approval cancer cell treatment for

---

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Published: 2024-04-23 (Crawled : 07:00) - biospace.com/
IBRX | $4.815 -12.3% -14.02% 7.9M |

Manufacturing

| -8.63% | O: 16.59% H: 0.65% C: -10.73%
il-15 anktiva fda agonist approval bladder cancer for

---

Gainers vs Losers

62%

38%

Top 10 Gainers

CSSE 4 | $0.4323 183.85% 64.77% 220M |

Consumer Services

BOF | $1.99 70.09% 41.21% 110M |

ILAG | $0.51 6.03% 40.62% 1.7M |

LICN | $0.941 68.04% 40.49% 15M |

AMST | $3.31 65.5% 39.58% 70M |

Technology Services

MTC | $3.615 61.38% 38.04% 9.3M |

Technology Services

WIMI | $1.15 58.53% 36.92% 19M |

Technology Services

AIH | $0.45 12.5% 30.92% 320K |

Health Services

MULN | News | $3.78 38.46% 27.78% 13M |

Information

RILY | $29.86 37.48% 27.26% 12M |

Finance

---

Your saved searches

---